Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:a677f6963fb51d78a59bf5d7c9290747]
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Will be analyzed independently for each stratum (osteosarcoma and Ewing sarcoma). Will be described using frequency, percentage, and 95% confidence interval (binomial law).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:a677f6963fb51d78a59bf5d7c9290747]
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Will be analyzed independently for each stratum (osteosarcoma and Ewing sarcoma). Will be described using frequency, percentage, and 95% confidence interval (binomial law).
Bio2RDF identifier
a677f6963fb51d78a59bf5d7c9290747
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a677f6963fb51d78a59bf5d7c9290747
measure [clinicaltrials_vocabulary:measure]
Non-progression, defined as co ...... stable disease (osteosarcoma)
time frame [clinicaltrials_vocabulary:time-frame]
At 6 months
description
The best overall response is t ...... dence interval (binomial law).
identifier
clinicaltrials_resource:a677f6963fb51d78a59bf5d7c9290747
title
Non-progression, defined as co ...... ase (osteosarcoma) At 6 months
@en
type
label
Non-progression, defined as co ...... 7f6963fb51d78a59bf5d7c9290747]
@en